Report interim data from Phase 2 study with ABI-H2158
The company cancelled or abandoned the commitment
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 31 Dec 2021
- Withdrawn
- 1 Sep 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Anticipate interim data from Phase 2 study with ABI-H2158 in H2 2021.”
What we found
Evidence strength A What the grades mean
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2021.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Interim data from Phase 2 study with ABI-H2158
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Assembly Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ASMB-024646 · Corrections policy